About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Same Targets To Block Cancer And Combat Down Syndrome

by Gopalan on April 27, 2011 at 6:02 AM
Font : A-A+

 Same Targets To Block Cancer And Combat Down Syndrome

Dana-Farber Cancer Institute scientists believe they have identified targets that could be useful in both cancer treatment and tackling the Down syndrome.

The life of a cell is defined by phases in which it grows, creates a duplicate set of chromosomes, and divides into two daughter cells ¡ª all governed by external signals such as growth-stimulating factors and internal ¡°checkpoints.¡± Cells can also exit the growth cycle in two ways ¡ª becoming quiescent or inactive (which most of our cells are most of the time) until they re-enter the growth cycle, or senescent. Cells entering senescence are damaged or nearing the end of their lives, and ultimately die.

Advertisement

Cancer cells survive, in part, by ignoring signals to become senescent and continuing to make copies of themselves at will, or by entering a quiescent state from which they can be re-activated. Scientists don¡¯t have a good understanding of how cells negotiate the molecular checkpoints that control these transitions.

¡°Our study identifies a molecular switch required for entry into quiescence and senescence,¡± said James A. DeCaprio, MD, whose laboratory group focuses on cell cycle regulation.
Advertisement

The gatekeeper to cell senescence and quiescence is a group of eight proteins that assemble themselves into the so-called DREAM complex, which helps cells exit the active cycle by turning off more than 800 growth-related genes.

A key player that triggers the assembly of the DREAM team is p130, a member of the Rb family of proteins. DeCaprio said the new research highlights p130¡äs underappreciated role in DREAM action. ¡°We have for the first time linked p130 itself to quiescence and senescence¡± ¡ª the latter contributing to cancer formation, said DeCaprio, who is also an associate professor of medicine at Harvard Medical School.

The report also for the first time reveals that a molecular switch, an enzyme called DYRK1A, performs a crucial step in assembling the p130-DREAM complex, and thus is novel control point for quiescence and senescence. When DYRK1A is turned on, it acts through p130 to set in motion the assembly of DREAM, which turns off the growth genes and allows cells to depart the growth cycle and become quiescent or senescent.

DYRK1A¡¯s ability to turn off cell growth genes may also be involved in the lower-than-normal development of brain neurons in Down syndrome, say the scientists, who are investigating possible new avenues to treating the disorder.

While they tend to have cognitive losses, people with Down syndrome have a markedly lower risk of most types of cancer. DYRK1A is made by a gene on chromosome 21, which is present in three copies instead of the normal two in people with Down syndrome, causing the enzyme to be overproduced. DeCaprio said this abnormal activity could explain both outcomes: DYRKIA-triggered DREAM formation could help suppress cancers by driving them into senescence, and also reduce the generation of brain cells during development.

The researchers have thus revealed a previously unrecognized link between two cell-signaling pathways, called Rb and Hippo in scientific shorthand, that help regulate the formation of cells and organs during early development. Both pathways are frequently disrupted in cancer.

They show that a component of the Hippo pathway, a protein called LATS2, can activate DYRK1A.

The authors said that LATS2 gene is located in an area frequently missing in cancer cells, suggesting that LATS2 might be a new control point for suppressing cancer cell growth.

The findings are carried in two papers published in Genes & Development.

DeCaprio is the senior author and Larisa Litovchick, PhD, also of Dana-Farber, is the first author of one of the papers. They also are co-authors on the second article, whose senior author is Nicholas Dyson, PhD, at Massachusetts General Hospital Cancer Center.



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test  Your Knowledge on Heart
Test Your Knowlege on Genes
Obesity in Teens Make Inroads into Early Atrial Fibrillation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Cancer Facts Cancer Tattoos A Body Art Down Syndrome Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 

Most Popular on Medindia

A-Z Drug Brands in India Drug - Food Interactions Loram (2 mg) (Lorazepam) Sanatogen Hearing Loss Calculator Sinopril (2mg) (Lacidipine) Vent Forte (Theophylline) Diaphragmatic Hernia Indian Medical Journals Pregnancy Confirmation Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Same Targets To Block Cancer And Combat Down Syndrome Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests